Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicines. Co.'s primary product candidates are: Tamibarotene, which is a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine; SY-2101, which is an oral form of arsenic trioxide; and SY-5609, which is a selective oral inhibitor of cyclin-dependent kinase 7 that is being evaluated in combination with chemotherapy in relapsed/refractory metastatic pancreatic cancer patients. We show 32 historical shares outstanding datapoints in our SYRS shares outstanding history coverage, used to compute SYRS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SYRS market cap history over the course of time is important for investors
interested in comparing SYRS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SYRS versus a peer is one thing; comparing
SYRS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SYRS can fluctuate over the course of history.
With this page we aim to empower investors researching SYRS by allowing them to research the SYRS market cap history. |
Free SYRS Email Alerts:
Video: The Importance of Market Cap
